<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612532</url>
  </required_header>
  <id_info>
    <org_study_id>LuCID-2</org_study_id>
    <nct_id>NCT02612532</nct_id>
  </id_info>
  <brief_title>Lung Cancer Indicator Detection</brief_title>
  <acronym>LuCID</acronym>
  <official_title>Lung Cancer Indicator Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Owlstone Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universit√§tsklinikum Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glenfield Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peterborough and Stamford Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals of North Midlands NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buckinghamshire Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wirral University Teaching Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Tyneside and Sunderland NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research and Trials Unit (Norfolk &amp; Norwich University Hospital, UK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barnet and Chase Farm Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Owlstone Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Lung Cancer Indicator Detection (LuCID) study investigates the the diagnostic accuracy of&#xD;
      FAIMS for diagnosis of lung cancer by analysis of exhaled Volatile Organic Compounds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Approximately 75% of patients with lung cancer present with advanced disease. For&#xD;
      those with stage 1 disease, the chance of cure is up to 70%. Therefore, diagnostics which may&#xD;
      aid identification of those with early stage lung cancer will play an important role in&#xD;
      future screening programs. Because all cancer cells are characterized by a change in their&#xD;
      metabolism related to their uncontrolled growth, detection of the resulting metabolites may&#xD;
      be a novel diagnostic tool for early stage lung cancer. Subsets of these metabolites are&#xD;
      volatile and are exhaled as so-called volatile organic compounds (VOCs). Analysis of exhaled&#xD;
      VOCs suggests they differ between patients with advanced lung cancer and healthy controls.&#xD;
      The Lung Cancer Indicator Detection (LuCID) study aims to validate the use of a&#xD;
      high-throughput breath analysis technique in a population of patients whom are clinically&#xD;
      suspected of having lung cancer.&#xD;
&#xD;
      Methods LuCID is an international, multi-center case-control study. Patients referred by&#xD;
      their GP or treating specialist for a diagnostic work-up for lung cancer will be invited to&#xD;
      participate in the study. A maximum of two thousand five hundred patients whom consent to&#xD;
      partake in this study will be asked to provide a breath sample prior to any diagnostic&#xD;
      procedures. This is a non-invasive procedure that will require the patient to breath normally&#xD;
      into a facemask to collect 2.5L of breath amounting to approximately 10 minutes of breathing.&#xD;
      The resulting samples will be analyzed for VOCs by Gas Chromatography coupled to Mass&#xD;
      Spectrometry and Gas Chromotography coupled to Field Assymetrical Ion Mobility Spectrometry.&#xD;
      The resulting VOC profiles will be used to generate a diagnostic algorithm in order to try to&#xD;
      differentiate between patients with and without lung cancer in the intention to diagnose&#xD;
      population. This study will not interfere in any with the standard care offered at the&#xD;
      clinical sites.&#xD;
&#xD;
      Outcomes The results of this study will provide detailed insights into the accuracy of the&#xD;
      test for the detection of lung cancer in the intention to diagnose population. This will form&#xD;
      the foundation for a subsequent study in a population at risk for the development of lung&#xD;
      cancer. If sufficiently accurate for early stage disease, analysis of breath VOCs could help&#xD;
      implement large-scale screening for lung cancer, significantly decreasing the morbidity and&#xD;
      mortality of the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve for the diagnostic algorithm for lung cancer with optimal point sensitivity, specificity negative and positive predictive values.</measure>
    <time_frame>2 years</time_frame>
    <description>Diagnostic accuracy of VOC analysis for Lung Cancer diagnosis based on pattern recognition analysis of raw VOC-spectra generated by Lonestar analysis of breath.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction of within group variability in exhaled VOCs explained by factors not primarily related to disease proces</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of potential parameters affecting exhaled VOCs other than lung cancer such as smoking, diet and co-morbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identified exhaled biomarkers associated with tumor stage and size.</measure>
    <time_frame>2 years</time_frame>
    <description>Analysis of correlation between exhaled biomarkers and the type, stage and size of the pulmonary tumor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>LuCID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardised exhaled volatile organic compound collection by &quot;ReCIVA&quot; breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReCIVA breath sampler</intervention_name>
    <description>Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva</description>
    <arm_group_label>LuCID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recruitment for these patients will be done from NHS hospitals whom identify or follow-up&#xD;
        on patients suspected of having lung cancer.&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               -  Older than 18 years at time of consent&#xD;
&#xD;
               -  Referred for investigation due to suspicion of lung cancer&#xD;
&#xD;
                    -  Referral based on suspicious symptoms&#xD;
&#xD;
                    -  Referral based on suspicious finding on imaging, including CTscan with&#xD;
                       indeterminate nodule requiring follow-up evaluation.&#xD;
&#xD;
               -  Capable of understanding written and/or spoken language&#xD;
&#xD;
               -  Able to provide informed consent&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  (Anticipated) inability to complete breath sampling procedure due to e.g. hyper-&#xD;
                  or hypo-ventilation, respiratory failure or claustrophobia when wearing the&#xD;
                  sampling mask&#xD;
&#xD;
               -  Participating in a Clinical Trial Investigational Medicinal Product (CTIMP)&#xD;
&#xD;
               -  Pulmonary function test with metacholine or beta-2-sympatico mimetic in last 2&#xD;
                  hours.&#xD;
&#xD;
               -  Any lung biopsy in the past 48 hours&#xD;
&#xD;
               -  Currently undergoing anti-cancer treatment for lung cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc P van der Schee, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Owlstone Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZA University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZG University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PapworthHospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wycombe</name>
      <address>
        <city>Buckingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watford Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough and Stamford Hospital</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital NHS Trust</name>
      <address>
        <city>Stoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wirral University Teaching Hospital NHS Foundation Trust</name>
      <address>
        <city>Upton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.owlstonenanotech.com/lucid</url>
    <description>LuCID study homepage</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

